Cargando…
Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants
Remimazolam is a novel general anesthetic and its safety in patients with malignant hyperthermia (MH) is unknown. We used myotubes derived from the skeletal muscle of patients with MH to examine the response to ryanodine receptor 1 (RYR1) agonist and remimazolam in MH-susceptible patients. Patients...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671487/ https://www.ncbi.nlm.nih.gov/pubmed/38002952 http://dx.doi.org/10.3390/genes14112009 |
_version_ | 1785140168433336320 |
---|---|
author | Miyoshi, Hirotsugu Otsuki, Sachiko Mukaida, Keiko Kido, Kenshiro Sumii, Ayako Ikeda, Tsuyoshi Noda, Yuko Yasuda, Toshimichi Narasaki, Soshi Kato, Takahiro Kamiya, Satoshi Horikawa, Yousuke T. Tsutsumi, Yasuo M. |
author_facet | Miyoshi, Hirotsugu Otsuki, Sachiko Mukaida, Keiko Kido, Kenshiro Sumii, Ayako Ikeda, Tsuyoshi Noda, Yuko Yasuda, Toshimichi Narasaki, Soshi Kato, Takahiro Kamiya, Satoshi Horikawa, Yousuke T. Tsutsumi, Yasuo M. |
author_sort | Miyoshi, Hirotsugu |
collection | PubMed |
description | Remimazolam is a novel general anesthetic and its safety in patients with malignant hyperthermia (MH) is unknown. We used myotubes derived from the skeletal muscle of patients with MH to examine the response to ryanodine receptor 1 (RYR1) agonist and remimazolam in MH-susceptible patients. Patients underwent muscle biopsy for the Ca(2+)-induced Ca(2+) release (CICR) rate test, a diagnostic tool for MH in Japan. Ten patients had myotubes obtained from skeletal muscle cultures, and the genes associated with malignant hyperthermia in these patients were analyzed. The EC(50) of caffeine, cresol, and remimazolam to induce intracellular calcium concentration change were compared between myotubes from CICR-negative genetic test patients and myotubes from other patients. Eight of the ten were CICR-positive, five of whom had RYR1 causative gene mutations or variants. Two patients had CICR-negative genetic tests, and as expected had the highest EC(50) (the concentration of a drug that gives a half-maximal response) in response to caffeine, 4CmC and remimazolam. Three patients had a positive CICR but no known variants in RYR1 or CACNA1S (voltage-gated calcium channel subunit alpha1S). Myotubes in these patients had significantly lower EC50s for all agents than myotubes in CICR-negative patients. When myotubes from a patient who was CICR-negative and had no gene variant were used as a control, myotubes from CICR-positive patients were more hyper-responsive than controls to all stimulants used. The EC(50) for remimazolam was lowest for myotubes from CICR-positive, RYR1-mutant patients, at 206 µM (corresponding to 123 µg/mL). The concentration was more than 80-times higher than the clinical concentration. RYR1 gene variants in R4645Q and W5020G were shown to be causative gene mutations for MH. Intracellular calcium in myotubes from MH patients are elevated at high concentrations of remimazolam but not at clinically used concentrations of remimazolam. Remimazolam appears to be safe to use in patients with MH. |
format | Online Article Text |
id | pubmed-10671487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106714872023-10-27 Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants Miyoshi, Hirotsugu Otsuki, Sachiko Mukaida, Keiko Kido, Kenshiro Sumii, Ayako Ikeda, Tsuyoshi Noda, Yuko Yasuda, Toshimichi Narasaki, Soshi Kato, Takahiro Kamiya, Satoshi Horikawa, Yousuke T. Tsutsumi, Yasuo M. Genes (Basel) Article Remimazolam is a novel general anesthetic and its safety in patients with malignant hyperthermia (MH) is unknown. We used myotubes derived from the skeletal muscle of patients with MH to examine the response to ryanodine receptor 1 (RYR1) agonist and remimazolam in MH-susceptible patients. Patients underwent muscle biopsy for the Ca(2+)-induced Ca(2+) release (CICR) rate test, a diagnostic tool for MH in Japan. Ten patients had myotubes obtained from skeletal muscle cultures, and the genes associated with malignant hyperthermia in these patients were analyzed. The EC(50) of caffeine, cresol, and remimazolam to induce intracellular calcium concentration change were compared between myotubes from CICR-negative genetic test patients and myotubes from other patients. Eight of the ten were CICR-positive, five of whom had RYR1 causative gene mutations or variants. Two patients had CICR-negative genetic tests, and as expected had the highest EC(50) (the concentration of a drug that gives a half-maximal response) in response to caffeine, 4CmC and remimazolam. Three patients had a positive CICR but no known variants in RYR1 or CACNA1S (voltage-gated calcium channel subunit alpha1S). Myotubes in these patients had significantly lower EC50s for all agents than myotubes in CICR-negative patients. When myotubes from a patient who was CICR-negative and had no gene variant were used as a control, myotubes from CICR-positive patients were more hyper-responsive than controls to all stimulants used. The EC(50) for remimazolam was lowest for myotubes from CICR-positive, RYR1-mutant patients, at 206 µM (corresponding to 123 µg/mL). The concentration was more than 80-times higher than the clinical concentration. RYR1 gene variants in R4645Q and W5020G were shown to be causative gene mutations for MH. Intracellular calcium in myotubes from MH patients are elevated at high concentrations of remimazolam but not at clinically used concentrations of remimazolam. Remimazolam appears to be safe to use in patients with MH. MDPI 2023-10-27 /pmc/articles/PMC10671487/ /pubmed/38002952 http://dx.doi.org/10.3390/genes14112009 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Miyoshi, Hirotsugu Otsuki, Sachiko Mukaida, Keiko Kido, Kenshiro Sumii, Ayako Ikeda, Tsuyoshi Noda, Yuko Yasuda, Toshimichi Narasaki, Soshi Kato, Takahiro Kamiya, Satoshi Horikawa, Yousuke T. Tsutsumi, Yasuo M. Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants |
title | Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants |
title_full | Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants |
title_fullStr | Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants |
title_full_unstemmed | Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants |
title_short | Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants |
title_sort | effects of remimazolam on intracellular calcium dynamics in myotubes derived from patients with malignant hyperthermia and functional analysis of type 1 ryanodine receptor gene variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671487/ https://www.ncbi.nlm.nih.gov/pubmed/38002952 http://dx.doi.org/10.3390/genes14112009 |
work_keys_str_mv | AT miyoshihirotsugu effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT otsukisachiko effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT mukaidakeiko effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT kidokenshiro effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT sumiiayako effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT ikedatsuyoshi effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT nodayuko effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT yasudatoshimichi effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT narasakisoshi effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT katotakahiro effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT kamiyasatoshi effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT horikawayousuket effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants AT tsutsumiyasuom effectsofremimazolamonintracellularcalciumdynamicsinmyotubesderivedfrompatientswithmalignanthyperthermiaandfunctionalanalysisoftype1ryanodinereceptorgenevariants |